Leaderboard
Anzeige
tellmed.ch
En
|
De
Impressum
Sie sind hier:
Gastroenterologie
»
Magen-Darm
»
Funktionelle Beschwerden
13. Juni 2026
Suchen
medline.ch
Funktionelle Beschwerden
Erweiterte Suche
Dermatologie
Endokrinologie
Ernährung
Gastroenterologie
Gallenwege
Leber
Magen-Darm
Diarrhoe
Entzündliche Darmerkrankungen
Funktionelle Beschwerden
Gastroenteritis
Gastrointestinale Hämorrhagie
Neoplasie
Peptische Ulzera
Anderes
Oesophagus
Pankreas
Gynäkologie
Hämatologie
Infektiologie
Kardiovaskuläre Erkrankungen
Muskuloskelettale Erkrankungen
Neurologie
Onkologie
Ophthalmologie
ORL
Pädiatrie
Psychiatrie
Respirationstrakt
Sportmedizin
Urologie-Nephrologie
Schrift:
Rect Top
Anzeige
Seite 1 von 478
Artikel 1 - 20 / 9544
Residential green space mitigates genetic susceptibility to incident irritable bowel syndrome in a prospective cohort of 376 749 individuals.
J Glob Health
Kou Z, Li R, Wang J, Shao Z, Feng J, Wei M, Fu T, Chen L, Zheng G, Lin H, Liu K.
PMID: 42281490 [PubMed - indexed for MEDLINE]
Correction to 'Effects of a Personalised FODMAP Diet Versus the National Institute for Health and Care Excellence (NICE) Dietary Advice on Symptom Control in Patients With Irritable Bowel Syndrome: Randomised Clinical Trial'.
Aliment Pharmacol Ther
PMID: 42276969 [PubMed - as supplied by publisher]
Outcomes for a digital prescription mobile application for adults with irritable bowel syndrome: an uncontrolled trial.
BMC Gastroenterol
Butt MF, Reghefaoui M, Bush D, Aliyu A, Darie AM, Mohanan A, Sibelli A, Card TR, Corsetti M.
PMID: 42271261 [PubMed - as supplied by publisher]
Acupuncture-like transcutaneous electrical nerve stimulation for patients with irritable bowel syndrome: Pilot mixed-methods study.
J Bodyw Mov Ther
Fang TY, Lin TT, Yang CS, Chiang HC, Liu CY, Chien CH.
PMID: 42264839 [PubMed - indexed for MEDLINE]
Correction to: Long-Term Safety of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation in the T3MPO-3 Study.
Neurogastroenterol Motil
PMID: 42252906 [PubMed - in process]
Comment on "Efficacy and Safety of Postbiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis".
J Gastroenterol Hepatol
Zhu J, Qiu X, Ma R.
PMID: 42252522 [PubMed - as supplied by publisher]
Gut microbiota signatures differentiate trajectory-defined response phenotypes and predict self-management outcomes in irritable bowel syndrome.
medRxiv
Chen J, Li A, Wu W, Xu W, Zhao T, Starkweather AR, Rodriguez L, Chen MH, Cong XS.
PMID: 42238447 [PubMed]
Reassessing Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Comparative Study of Diagnostic Guidelines and Their Clinical Relevance.
J Gastroenterol Hepatol
Loh AJC, Loo QY, Ng AK, Khoo XH, Siah KT, Abdul Majid H, Mahadeva S, Chuah KH.
PMID: 42235989 [PubMed - as supplied by publisher]
Multi-omics mendelian randomization integrating GWAS and eQTL data revealed potential drug target for irritable bowel syndrome.
Front Genet
Ke H, Chen W, Zhang Q, Liu Z, Wei P, Li L, Yu H, Huang D, Lan C, Xu N, Pi L, Song K.
PMID: 42232515 [PubMed]
Bodily Maps of Emotions in Irritable Bowel Syndrome: A Case-Control Study.
Neurogastroenterol Motil
Dens K, Van Den Houte M, Tack J, Toelen J, Dupont P, Van Oudenhove L.
PMID: 42226507 [PubMed - indexed for MEDLINE]
Comparative Effectiveness of Hangeshashinto and Ramosetron for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Digestion
Nishida K, Hirata Y, Murano M, Mitooka H, Sugishima S, Nakazawa K, Koshiba R, Kakimoto K, Miyazaki T, Nakamura S, Nishikawa H.
PMID: 42224387 [PubMed - as supplied by publisher]
Feasibility and efficacy of fecal microbiota transplantation in adolescents with refractory irritable bowel syndrome: A randomized clinical pilot trial.
J Pediatr Gastroenterol Nutr
de Bruijn CMA, Oorthuys AOJ, Zeevenhooven J, Davids M, Levels JHM, Vlieger AM, Herrema H, Nieuwdorp M, Benninga MA.
PMID: 42220281 [PubMed - as supplied by publisher]
Dietary habits and their association with irritable bowel syndrome among the public population in Saudi Arabia: a multicenter based study.
Front Public Health
Qalawa SAA, Elbqry MG, Elmansy FM, Almunif AT, Alharbi BF, Alharbi RJ, Alharbi JA, Alharbi KM, Almuhaysin SA, Almutairi ST, Albashir WM.
PMID: 42211719 [PubMed - indexed for MEDLINE]
Efficacy and safety of modified Gwakjeongtang (herbal medicine) for diarrhea-predominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial.
Integr Med Res
Choi Y, Ha NY, Kim AR, Kwon O, Jeong H, Yuk HJ, Park KS, Kim J, Kim J, Kim H.
PMID: 42211410 [PubMed]
Characterizing Abdominal Pain and Irritable Bowel Syndrome Among Individuals With Cirrhosis: Results of a Nationwide Survey.
Gastro Hep Adv
Deng LX, Almario CV, Lai JC, Spiegel BMR, Rubin JB.
PMID: 42205170 [PubMed]
Application of neuromodulation techniques in irritable bowel syndrome.
Front Neurosci
Zhang Y, Gao L, Zhang X, Sun W, Wang M, Zhang T, Wang X.
PMID: 42200039 [PubMed]
Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications.
Pharmaceuticals (Basel)
Pastras P, Aggeletopoulou I, Psalti V, Triantos C.
PMID: 42198457 [PubMed]
Effects of γ-Aminobutyric Acid (GABA) Supplementation on Symptoms, Quality of Life, Intestinal Permeability, Systemic Inflammation and Gut Microbiota in Patients with IBS-D: A Randomized, Double Blind, Placebo-Controlled, Crossover Pilot Study.
Nutrients
Lambiase C, Cancelli L, Tedeschi R, Grosso A, Rettura F, Salemmo R, Bottari A, Filippini F, Salvadori S, Valdiserra G, Campigli L, Antonioli L, Fornai M, de Bortoli N, Bellini M.
PMID: 42197028 [PubMed - indexed for MEDLINE]
Long-Term Risk of Parkinson's Disease Following Irritable Bowel Syndrome: A Nationwide Population-Based Cohort Study.
Healthcare (Basel)
Bae Y, Seo S, Jeon SR, Dong JJ, Lee SW, Jung H.
PMID: 42194421 [PubMed]
Consensus on Irritable Bowel Syndrome-like Symptoms in Inflammatory Bowel Disease: A Step Toward Advancing Patient-Centered Care.
Gastroenterology
Burisch J, Marsiglio M, Keszthelyi D.
PMID: 42191045 [PubMed - as supplied by publisher]
Artikel 1 - 20 / 9544
Seite 1 von 478
Rect Bottom
Anzeige
Adserver Footer
Zeitfenster
--unbegrenzt--
1 Woche
1 Monat
3 Monate
6 Monate
1 Jahr
2 Jahre
3 Jahre
5 Jahre
10 Jahre
Sky right 1
Anzeige
Mediscope AG E-mail:
info@mediscope.ch
Disclaimer
|
Datenschutzerklärung / Privacy Policy
|
Werbung